gastric cancer

The company also plans to submit a new drug application for avapritinib in mainland China in the first half of this year. 

The trial evaluated the safety and preliminary activity of the single-agent therapy for FGFR2b-overexpressing gastric cancers.

The partnership aims to analyze the differences in the tumor microenvironments of cancer patients and use that to classify tumors and determine treatment prognosis.

The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.

A phylogenetic analysis that included multiple samples per patient suggests overlapping driver mutations make their way into multiple metastases in each patient.

Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.

An international team of researchers also suggested that MUC16 mutations could identify patients who might benefit from immunotherapy treatment.